Adjuvant Interferon Therapy for Patients with Uveal Melanoma at High Risk of Metastasis

Ophthalmology

Volumn 116, Issue 11, 2009, Pages 2206-2212

  Lane, Anne Marie ^a   Egan, Kathleen M ^b   Harmon, David ^c   Holbrook, Amy ^a   Munzenrider, John E ^c   Gragoudas, Evangelos S ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTHRALGIA; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILL; CHOROID CANCER; CILIARY BODY; CILIARY BODY TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENUCLEATION; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFLUENZA; LETHARGY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; PRIORITY JOURNAL; PROTON THERAPY; RANDOMIZED CONTROLLED TRIAL; SCLERECTOMY; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTOPENIA; THYROID FUNCTION; TUMOR VOLUME; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; EYE ENUCLEATION; FEMALE; HUMANS; INTERFERON ALFA-2A; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 70350574114     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.04.044     Document Type: Article

References (41)

1. Gragoudas E., Li W., Goitein M., et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 120 (2002) 1665-1671
2. Sparano J.A., Lipsitz S., Wadler S., et al. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer: Eastern Cooperative Oncology Group Protocol 3292. Am J Clin Oncol 19 (1996) 546-551
3. Escudier B., Pluzanska A., Koralewski P., et al., AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
4. Hudes G., Carducci M., Tomczak P., et al., Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
5. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
6. Pyrhonen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 (1999) 2859-2867
7. Cascinelli N., Belli F., MacKie R.M., et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358 (2001) 866-869
8. Atzpodien J., Lopez Hanninen E., Kirchner H., et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 31A (1995) 876-881
9. Groenewegen G., Bloem A., and De Gast G.C. Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. Cancer Immunol Immunother 51 (2002) 630-636
10. Becker J.C., Terheyden P., Kampgen E., et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 87 (2002) 840-845
11. Kivela T., Suciu S., Hansson J., et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 39 (2003) 1115-1120
12. Nathan F.E., Berd D., Sato T., et al. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res 16 (1997) 201-208
13. Pyrhonen S., Hahka-Kemppinen M., Muhonen T., et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer 95 (2002) 2366-2372
14. Solti M., Berd D., Mastrangelo M.J., and Sato T. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res 17 (2007) 225-231
15. de Waard-Siebinga I., Creyghton W.M., Kool J., and Jager M.J. Effects of interferon alfa and gamma on human uveal melanoma cells in vitro. Br J Ophthalmol 79 (1995) 847-855
16. Grob J.J., Dreno B., de la Salmoniere P., et al., French Cooperative Group on Melanoma. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 351 (1998) 1905-1910
17. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
18. Legha S.S., Papadopoulos N.E., Plager C., et al. Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5 (1987) 1240-1246
19. Creagan E.T., Ahmann D.L., Green S.J., et al. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 2 (1984) 1002-1005
20. Creagan E.T., Ahmann D.L., Green S.J., et al. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer 54 (1984) 2844-2849
21. Cascinelli N., Bufalino R., Morabito A., and Mackie R. Results of adjuvant interferon study in WHO melanoma programme [letter]. Lancet 343 (1994) 913-914
22. Sisley K., Cottam D.W., Rennie I.G., et al. Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma. Genes Chromosomes Cancer 5 (1992) 197-200
23. Edmunds S.C., Cree I.A., Di Nicolantonio F., et al. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 88 (2003) 1403-1405
24. Monzon J., Liu L., Brill H., et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338 (1998) 879-887
25. Brantley Jr. M.A., and Harbour J.W. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 157 (2000) 1795-1801
26. Edmunds S.C., Kelsell D.P., Hungerford J.L., and Cree I.A. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest Ophthalmol Vis Sci 43 (2002) 2845-2851
27. Ross D.A., and Wilson G.D. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br J Surg 85 (1998) 46-51
28. Grover R., Ross D.A., Wilson G.D., and Sanders R. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma. Br J Plast Surg 50 (1997) 478-482
29. Chana J.S., Wilson G.D., Cree I.A., et al. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol 83 (1999) 110-114
30. Tulley P.N., Neale M., Jackson D., et al. The relation between c-myc expression and interferon sensitivity in uveal melanoma. Br J Ophthalmol 88 (2004) 1563-1567
31. Yang H., Dithmar S., and Grossniklaus H.E. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells. Invest Ophthalmol Vis Sci 45 (2004) 2056-2064
32. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18 (2000) 2444-2458
33. Rusciani L., Petraglia S., Alotto M., et al. Postsurgical adjuvant therapy for melanoma: evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer 79 (1997) 2354-2360
34. Dithmar S., Rusciano D., Lynn M.J., et al. Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol 118 (2000) 1085-1089
35. Eskelin S., Pyrhonen S., Summanen P., et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 107 (2000) 1443-1449
36. Rajan G.P., Seifert B., Prummer O., et al. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Arch Dermatol Res 288 (1996) 543-548
37. Prummer O., and Delta-P Study Group. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. Cancer 71 (1993) 1828-1834
38. Ronnblom L.E., Janson E.T., Perers A., et al. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin Exp Immunol 89 (1992) 330-335
39. Kirkwood J.M., Manola J., Ibrahim J., et al. A pooled analysis of Eastern Cooperative Oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10 (2004) 1670-1677
40. Yang H., and Grossniklaus H.E. Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res 31 (2006) 557-562
41. Alizadeh H., Howard K., Mellon J., et al. Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. Invest Ophthalmol Vis Sci 44 (2003) 3042-3051